Related Experiment Video
Updated: Dec 21, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
[Pharmaceutical care for severe and critically ill patients with COVID-19]
Saiping Jiang1, Lu Li1, Renping Ru2
1The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Abstract:
Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Coronary Syndrome IV: Interprofessional Care
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Psychosis: Goals of Pharmacotherapy
Acute Coronary Syndrome V: Nursing Management
Acute Respiratory Failure-IV

